U.S. markets close in 17 minutes
  • S&P 500

    3,829.23
    +43.85 (+1.16%)
     
  • Dow 30

    31,136.22
    +360.79 (+1.17%)
     
  • Nasdaq

    11,128.00
    +99.26 (+0.90%)
     
  • Russell 2000

    1,723.03
    +15.04 (+0.88%)
     
  • Crude Oil

    108.40
    +2.64 (+2.50%)
     
  • Gold

    1,808.70
    +1.40 (+0.08%)
     
  • Silver

    19.83
    -0.53 (-2.59%)
     
  • EUR/USD

    1.0432
    -0.0051 (-0.49%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2101
    -0.0074 (-0.61%)
     
  • USD/JPY

    135.2550
    -0.4730 (-0.35%)
     
  • BTC-USD

    19,308.67
    +301.62 (+1.59%)
     
  • CMC Crypto 200

    416.07
    -4.07 (-0.97%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Adaptive Biotechnologies
Adaptive Biotechnologies

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming 42nd Annual Cowen Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to present on Wednesday, March 9th at 6:50 a.m. Pacific Time / 9:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in our Immune Medicine and Minimal Residual Disease (MRD) businesses. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.


CONTACT: ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 Carrie Mendivil, Gilmartin Group investors@adaptivebiotech.com ADAPTIVE MEDIA Laura Cooper 205-908-5603 media@adaptivebiotech.com